ATLANTA — Within 10 years of vaccine introduction, HPV prevalence decreased 86% among females aged 14 to 19 years in the United States, and 71% in women aged 20 to 24 years, according to study findings presented at the CDC’s Epidemic Intelligence Service, or EIS, conference. Speaking during a news conference, Nancy McClung, P h D, an EIS officer in the CDC’s National Center for Immunization and Respiratory Diseases, called the findings “very encouraging.” “The HPV vaccine prevents HPV infections that cause cancer and other conditions, and cervical cancer is the most common cancer caused by HPV in females,” McClung said. “The CDC has been monitoring HPV infection among females in the United States since the vaccine was first introduced in 2006.” According to the study, McClung and colleagues used the National Health and Nutrition Examination Survey to evaluate quadrivalent vaccine (4vHPV)-type prevalence among 4,674 females in the prevaccine (2003–2006) and vaccine (2013–2016) eras...